In breast cancer, although DDB2 showed putative oncogenic behaviour by promoting cell-cycle progression [92], it was not over-expressed in ER-negative breast cancer cells [92, 93], e.g. SKBR3 [93]. Here, DDB2 is linked to breast carcinoma.